Editas Medicine Details In Vivo CRISPR Plan, Targets Year-End Human Proof-of-Concept for EDIT-401 [Yahoo! Finance]
Editas Medicine, Inc. (EDIT)
Last editas medicine, inc. earnings: 2/26 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.editasmedicine.com
Company Research
Source: Yahoo! Finance
Editas Medicine (NASDAQ:EDIT) executives outlined the company's in vivo CRISPR gene-editing strategy and near-term clinical plans during a recent discussion featuring President and CEO Gilmore O'Neill and CFO Amy Parison. The company emphasized a platform centered on intravenous delivery of CRISPR components using lipid nanoparticles (LNPs), with a focus on making targeted, non-coding DNA edits intended to upregulate protective proteins. In vivo CRISPR focus and differentiation O'Neill described Editas as “fully focused” on in vivo CRISPR therapeutics delivered via a “simple IV infusion” using LNPs. He said the company's approach is differentiated by using CRISPR to pursue biology that other modalities cannot, specifically by editing non-coding regions of DNA to increase expression of proteins that mitigate disease risk. ? Broadcom's AI Momentum Could Be Far From Over Are Gene Therapy Stocks The Market's Next Big Winners? As an example, O'Neill highlighted the company's LDL
Show less
Read more
Impact Snapshot
Event Time:
EDIT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EDIT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EDIT alerts
High impacting Editas Medicine, Inc. news events
Weekly update
A roundup of the hottest topics
EDIT
News
- Editas Medicine, Inc. (EDIT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
- Editas Medicine (EDIT) was upgraded by JonesTrading from "hold" to "buy". They now have a $8.00 price target on the stock.MarketBeat
- Editas Medicine (EDIT) was given a new $6.00 price target by Robert W. Baird.MarketBeat
- Editas Medicine (EDIT) had its "buy" rating reaffirmed by Chardan Capital. They now have a $3.50 price target on the stock.MarketBeat
- Editas Medicine (EDIT) had its "buy" rating reaffirmed by TD Cowen.MarketBeat
EDIT
Earnings
- 3/9/26 - Beat
EDIT
Sec Filings
- 3/16/26 - Form 4
- 3/16/26 - Form 4
- 3/16/26 - Form 4
- EDIT's page on the SEC website